8-K: Cosmos Health Reports Record Q2 & H1 2026 Revenue

Cosmos Health Inc. announced record Q2 and H1 2026 financial results, with revenues reaching $19.0M and $36.9M respectively, alongside significant improvements in adjusted gross profit and a reduction in total liabilities.

Summary

• Cosmos Health Inc. reported record-breaking revenue for the second quarter and first half of 2026, with Q2 revenue at $18.99 million (up 28.8% YoY) and H1 revenue at $36.91 million (up 29.7% YoY).
• Adjusted gross profit saw a substantial increase of 58.4% in Q2 to $1.84 million, with adjusted gross margin expanding by 165 basis points to 9.54%.
• The company strengthened its balance sheet, reducing total liabilities by 13.3% ($6.27 million) to $40.79 million and increasing stockholders' equity by 12.2% to $20.67 million.
• Operating expenses grew at approximately half the rate of revenue, indicating improved operating leverage.
• A $5 million share repurchase program was authorized, with $1.11 million worth of shares repurchased by August 19, 2026.
• Strategic growth initiatives include expansion in the UK, building contract manufacturing orderbooks, adding pharmacies to distribution networks, and international expansion of proprietary brands.
• New product development and market entries include the '18 Series' nutraceutical platform in the US and a veterinary formulation of C-Scrub Wash 4% for the animal health industry.
• The company is exploring potential financing of up to €25 million from the European Investment Bank for its R&D program and has identified approximately $20 million in non-core assets for monetization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting record revenues, improved gross margins, and a strengthened balance sheet, alongside strategic growth initiatives and a share repurchase program.

Positives

• Record Q2 and H1 revenue, reaching $18.99 million and $36.91 million respectively, driven by growth across all core segments.
• Significant increase in Q2 adjusted gross profit by 58.4% to $1.84 million, with adjusted gross margin expanding to 9.54%.
• Total liabilities decreased by 13.3% ($6.27 million) to $40.79 million, indicating improved financial health.
• Stockholders' equity increased by 12.2% to $20.67 million, strengthening the balance sheet.
• Operating expenses grew at roughly half the rate of revenue, demonstrating effective operating leverage.
• Active share repurchase program of up to $5.0 million is underway, signaling confidence in the company's valuation.
• Expansion of proprietary brands like Sky Premium Life across Europe and the UAE.
• Successful clinical validation and market entry for products like C-Scrub Wash 4% and C-Sept PRO, opening new channels.

Negatives

• Net loss for Q2 2026 was ($6.09 million), compared to ($2.83 million) in Q2 2025, and ($8.89 million) for H1 2026, compared to ($3.65 million) in H1 2025, largely due to non-cash charges.
• Adjusted EBITDA remained negative at ($1.13 million) for Q2 2026 and ($1.72 million) for H1 2026, although it showed improvement from the prior year's comparable periods.
• Adjusted net income (loss) was ($1.69 million) in Q2 2026 and ($2.65 million) for H1 2026, also indicating ongoing losses.
• Gross margin for H1 2026 declined to 7.84% from 11.29% in the prior year, primarily due to sales discount reversals.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including factors beyond the company's control.
• Potential impact of global conflicts (Ukraine, Middle East) on business operations and the economy.
• Challenges in raising sufficient financing to implement the business plan.
• Effectiveness of digital asset strategies, including accumulation and yield-generating activities.
• Changes in interest rates, foreign currency exchange rates, and commodity prices.
• Impact and expected outcome of investigations, inquiries, claims, and litigation.
• Challenges of operating in international markets.
• Adequacy of insurance coverage.

Future Outlook

The company expects increased efficiencies from economies of scale and vertical integration to play an important role in progressing toward sustained profitability. Momentum is expected to carry into Q3 2026 across every core segment, with the US platform beginning to contribute. The company also anticipates second-half seasonality to be materially stronger, as it was the previous year.

Management Comments

• "Q2 2026 was a record second quarter, with revenue of $18.99 million, up 29% year-over-year, capping a record first half of $36.91 million."
• "On an adjusted basis, this represents an annualized revenue run-rate in excess of $75 million – a new milestone for Cosmos."
• "Operating expenses grew at little more than half the rate of revenue, and we reduced both receivables and inventory while revenue grew nearly 30%. That is the operating leverage we have been building toward."
• "We also cut total liabilities by $6.3 million since year-end, lifting stockholders' equity 12% to $20.7 million and improving our liabilities-to-assets ratio by 550 basis points."
• "Moving forward, we are starting to see the benefits of economies of scale and vertical integration, and we expect increased efficiencies to play an important role as we progress toward sustained profitability."

Industry Context

StockSavvy.ai notes that Cosmos Health's reported revenue growth aligns with a broader trend in the healthcare sector of companies seeking to expand their product portfolios and geographical reach, particularly in specialized areas like nutraceuticals and contract manufacturing. The focus on proprietary brands and international expansion is a common strategy for diversified healthcare groups aiming to capture market share.

Comparison to Industry Standards

• The reported revenue growth of 29-30% for H1 2026 is strong compared to many established pharmaceutical and healthcare companies, which often see single-digit or low double-digit growth.
• The expansion of adjusted gross margin by 165 basis points is a positive indicator of operational efficiency, though the absolute margin of 9.54% is modest and may be lower than some specialized pharmaceutical manufacturers.
• The reduction in total liabilities and increase in stockholders' equity indicate a strengthening balance sheet, which is a key benchmark for financial stability in the healthcare industry.
• While the company is working towards profitability, the continued net loss and negative adjusted EBITDA suggest it is in a growth and investment phase, a common characteristic of companies expanding rapidly in the healthcare and biotech sectors.

Stakeholder Impact

• Shareholders: The share repurchase program may increase shareholder value by reducing outstanding shares and potentially boosting earnings per share. Positive financial results and future outlook could lead to increased investor confidence.
• Creditors: The reduction in total liabilities and strengthening of equity improves the company's creditworthiness and reduces financial risk for creditors.
• Employees: Growth in revenue and strategic investments may lead to job creation and opportunities within the expanding business segments.
• Suppliers: Increased production and distribution activities, particularly with Cana Laboratories' expanded orderbook and CosmoFarm's new pharmacies, suggest increased demand for supplies and services.

Next Steps

• Continue executing the $5 million share repurchase program.
• Expand the '18 Series' nutraceutical platform in the United States.
• Target EU expansion for C-Scrub and C-Sept products.
• Advance the international application of the CCX0722 weight-management hydrogel patent.
• Integrate AI across order management, warehouse, and supply chain operations.
• Complete the potential acquisition of Doc Pharma S.A.
• Monetize approximately $20 million in non-core assets.

Key Dates

Recommendation

The company shows strong revenue growth and operational improvements, but continues to report net losses and negative adjusted EBITDA. While the balance sheet is strengthening and a share repurchase program is active, the path to sustained profitability requires further execution and management of ongoing risks. A 'hold' recommendation reflects a balanced view of the positive momentum against the persistent profitability challenges.

Keywords

Cosmos Health, Q2 2026 Results, Revenue Growth, Gross Profit, Balance Sheet, Share Repurchase, Healthcare Group, Nutraceuticals